Skip to content

Supplementation in Adolescent Girls With Endometriosis

SAGE: Supplementation in Adolescent Girls With Endometriosis

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02387931
Acronym
SAGE
Enrollment
69
Registered
2015-03-13
Start date
2014-09-30
Completion date
2016-07-31
Last updated
2016-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Keywords

Adolescent, Endometriosis, Diet, Nutrition, Pain

Brief summary

The purpose of this study is to determine whether dietary supplementation with Vitamin D or Fish Oil can help to reduce physical and emotional symptoms in adolescent girls with endometriosis.

Detailed description

This is a randomized controlled trial designed to evaluate the effect of dietary supplementation on endometriosis symptom remediation. Adolescent and young adults females aged 12 to 25 years with a surgically-confirmed diagnosis of endometriosis will be eligible for study participation. Subjects will be excluded if they have concurrent chronic illnesses that affect gastrointestinal absorption of nutrients (e.g., celiac disease, IBD, cystic fibrosis), a history of renal stones, are pregnant, or non-English speaking. Once consented, subjects will be randomized to one of 3 treatment assignments: 1) vitamin D3 2000 IU daily (n=30), 2) fish oil 1000 mg daily (n=30), 3) placebo (n=30) and will take these daily for 6 months. Baseline nutrient intake from food and supplements will be assessed using the Food Frequency Questionnaire (FFQ). The 142 item survey assesses usual dietary intake during the past year. Validated rating scales including the visual analog scale (VAS), SF-36, and the World Endometriosis EPHect questionnaires will be used to measure pain and overall quality of life. The SF-36 measures 8 health concepts relevant across disease groups, including limitations to physical or social activities because of health problems, vitality, and general health perception. Patients will complete a full review of medication usage, past medical history, family history, and other lifestyle factors. Anthropometrics will be measured, and vital signs obtained. Measures will be repeated at 3-month intervals for a total of 6 months. Blood will be drawn at baseline, and at 6 months to measure levels of fatty acids, vitamin D, parathyroid hormone (PTH), and calcium.

Interventions

DIETARY_SUPPLEMENTVitamin D3

Nature Made Vitamin D 2000IU, 1 softgel taken daily

DIETARY_SUPPLEMENTFish Oil

Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily

OTHERPlacebo

Placebo capsule, 2 taken daily

Sponsors

Boston Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
12 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* Female * Age 12 years -25 years * Previously surgically diagnosed at Boston Children's Hospital with endometriosis * At least 6 weeks following laparoscopy * Minimum pain score within the 4 weeks preceding study baseline * Must be able to swallow an empty 00 gelatin capsule at baseline * Must be willing to stop all vitamins and nutritional supplements during trial

Exclusion criteria

* Concurrent chronic illnesses that affect gastrointestinal absorption of nutrients (e.g., celiac disease, IBD, cystic fibrosis) * Vitamin D level of greater than or equal to 100 ng/ml at study baseline * History of renal stones * No access to text messages or email * Pregnancy * Non-English speaking

Design outcomes

Primary

MeasureTime frameDescription
Endometriosis pain6 monthsMeasured by change in the score of the visual analog scale (VAS) from baseline to 6 months.

Secondary

MeasureTime frameDescription
Quality of life6 monthsMeasured by change in SF-36 and EPHect questionnaires from baseline to 6 months.
Pain medication usage6 monthsMeasured via questionnaire of medication usage from baseline to 6 months.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026